miRNA-21 as Reliable Serum Diagnostic Biomarker Candidate for Metastatic Progressive Prostate Cancer: Meta-analysis Approach.
biomarker
cancer
metastatic
miRNA-21
progressivity
prostate
Journal
Medical archives (Sarajevo, Bosnia and Herzegovina)
ISSN: 1986-5961
Titre abrégé: Med Arch
Pays: Bosnia and Herzegovina
ID NLM: 101635337
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
22
08
2021
accepted:
10
10
2021
entrez:
16
2
2022
pubmed:
17
2
2022
medline:
19
2
2022
Statut:
ppublish
Résumé
Prostate cancer is the second leading cause of cancer death in men, moreover when it develops metastasis. However, PSA detection in serum as current gold standard to measure disease progressivity had wide variability leading to confounding outcomes. MicroRNA-21 has diagnostic values for cancer over period of time researched, yet results are still inconclusive. The aim of the study was to conduct recent meta-analysis to assess reliability of miRNA-21 as diagnostic biomarker especially in progressivity of prostate cancer. Published papers from PubMed, Science Direct, and Embase" as of 1 July 2021 assessing circulating miRNA-21 in progressivity of prostate cancer patients were analyzed using Comprehensive Meta-Analysis tool. Pooled sensitivity, specificity, positive and negative likelihood ratio (LR) and SROC assessed with 95 % confidence intervals were estimated using fixed-effects or random-effects models. In total, we included 6 papers total of 651 samples reporting miRNA-21 capability of detecting progressive prostate cancer. The pooled sensitivity and specificity showed 0.91 (95% CI 0.88-0.94, I miRNA-21 could serve as biomarkers of prostate cancer progressivity since remarkable diagnostic value of circulating miRNA-21 in prostate cancer metastasis process.
Sections du résumé
BACKGROUND
BACKGROUND
Prostate cancer is the second leading cause of cancer death in men, moreover when it develops metastasis. However, PSA detection in serum as current gold standard to measure disease progressivity had wide variability leading to confounding outcomes. MicroRNA-21 has diagnostic values for cancer over period of time researched, yet results are still inconclusive.
OBJECTIVE
OBJECTIVE
The aim of the study was to conduct recent meta-analysis to assess reliability of miRNA-21 as diagnostic biomarker especially in progressivity of prostate cancer.
METHODS
METHODS
Published papers from PubMed, Science Direct, and Embase" as of 1 July 2021 assessing circulating miRNA-21 in progressivity of prostate cancer patients were analyzed using Comprehensive Meta-Analysis tool. Pooled sensitivity, specificity, positive and negative likelihood ratio (LR) and SROC assessed with 95 % confidence intervals were estimated using fixed-effects or random-effects models.
RESULTS
RESULTS
In total, we included 6 papers total of 651 samples reporting miRNA-21 capability of detecting progressive prostate cancer. The pooled sensitivity and specificity showed 0.91 (95% CI 0.88-0.94, I
CONCLUSION
CONCLUSIONS
miRNA-21 could serve as biomarkers of prostate cancer progressivity since remarkable diagnostic value of circulating miRNA-21 in prostate cancer metastasis process.
Identifiants
pubmed: 35169355
doi: 10.5455/medarh.2021.75.347-350
pmc: PMC8740671
doi:
Substances chimiques
Biomarkers
0
MIRN21 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
347-350Informations de copyright
© 2021 Kurnia Penta Seputra1, Basuki Bambang Purnomo, Hani Susianti, Handono Kalim, Athaya Febriantyo Purnomo.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Cell Cycle. 2010 Mar 1;9(5):923-9
pubmed: 20160498
Tumour Biol. 2014 Dec;35(12):12613-7
pubmed: 25190021
Cancer Biomark. 2016 Jul 8;17(2):223-30
pubmed: 27434290
Cancer Res. 2009 Sep 15;69(18):7165-9
pubmed: 19738047
Neoplasma. 2016;63(4):623-8
pubmed: 27268927
Biochem Biophys Res Commun. 2009 Jun 5;383(3):280-5
pubmed: 19302977
J Cell Biochem. 2018 Mar;119(3):2763-2786
pubmed: 29095529
J Mol Biol. 2008 May 2;378(3):492-504
pubmed: 18384814
Mol Cell. 2010 Aug 27;39(4):493-506
pubmed: 20797623
Cancer Biol Med. 2017 Nov;14(4):405-413
pubmed: 29372107
BMC Urol. 2012 May 29;12:14
pubmed: 22642976
Cancer Res. 2008 Oct 1;68(19):8164-72
pubmed: 18829576
Int J Surg. 2010;8(5):336-41
pubmed: 20171303
Am J Pathol. 2008 Jun;172(6):1717-28
pubmed: 18483213
Int Urol Nephrol. 2018 Sep;50(9):1619-1626
pubmed: 30014459
Life Sci. 2015 Sep 1;136:28-35
pubmed: 26144623
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Cent European J Urol. 2015;68(2):165-8
pubmed: 26251735
Int J Oncol. 2009 Nov;35(5):1175-82
pubmed: 19787273
Genet Test Mol Biomarkers. 2015 Sep;19(9):469-75
pubmed: 26247873
Asian Pac J Trop Med. 2017 Jan;10(1):87-91
pubmed: 28107872